NA
CLRB icon

NewEdge Advisors’s Cellectar Biosciences CLRB Stock Holding History

NewEdge Advisors’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,488
Closed -$178K – 3835
2024
Q1 		$178K Buy
1,488
+788
+113% +$85.4K ﹤0.01% 1881
2023
Q4 		$77.5K Buy
+700
New +$52.1K ﹤0.01% 2048

Other funds holding CLRB

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NewEdge Advisors's CLRB Position: Q2 2024 in Review

NewEdge Advisors sold out of Cellectar Biosciences (CLRB) in Q2 2024, closing a stake of 1,488 shares — an estimated $178K sold.

NewEdge Advisors first reported a position in CLRB in Q4 2023 and held it in 2 quarters. The position peaked at $178K in Q1 2024. 37 funds tracked by Wall St. Rank hold CLRB as of Q2 2024.

  • NewEdge Advisors reported no remaining Cellectar Biosciences position as of Q2 2024 after selling out during the quarter.
  • NewEdge Advisors sold 1,488 Cellectar Biosciences shares in Q2 2024, an estimated $178K.
  • NewEdge Advisors first reported a position in Cellectar Biosciences in Q4 2023 and held it in 2 quarters.
  • NewEdge Advisors's Cellectar Biosciences position peaked at $178K in Q1 2024.
  • 37 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2024.

Based on NewEdge Advisors's 13F filing for Q2 2024, filed 16 Aug 2024.